ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

AERI Aerie Pharmaceuticals Inc

15.25
0.00 (0.00%)
Pre Market
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 15.24
Ask Price 14.79
News -
Share Name Share Symbol Market Stock Type
Aerie Pharmaceuticals Inc AERI NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 15.25 19:00:00
Open Price Low Price High Price Close Price Previous Close
15.25
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0 US$ 15.25 USD

Aerie Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 753.62M - - - -20.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aerie Pharmaceuticals News

Real-Time news about Aerie Pharmaceuticals Inc (NASDAQ): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AERI Message Board. Create One! See More Posts on AERI Message Board See More Message Board Posts

Historical AERI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Aerie Pharmaceuticals Description

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Your Recent History

Delayed Upgrade Clock